Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.04.2015 | short review | Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia

memo - Magazine of European Medical Oncology > Ausgabe 1/2015
MD, PhD Lukas Weiss, MD Thomas Melchardt, MD Alexander Egle


B-cell receptor (BCR) inhibitors represent an exciting new treatment modality in chronic lymphocytic leukemia (CLL). Currently, ibrutinib monotherapy as well as idelalisib in combination with rituximab are approved by the European Medical Agency for the treatment of all patients with relapsed/refractory CLL and for first-line treatment of patients with deletion 17p or TP53 mutation unsuitable for chemoimmunotherapy. The results of ongoing trials with these and other BCR inhibitors are expected to lay the basis for approval in further indications, but have to be awaited. Above all, BCR inhibitors have shown to be able to fill the gap of urgently needed therapies for the elderly and comorbid CLL patient as well as the CLL patient with deletion 17p. BCR inhibitors might also challenge the role of allogeneic stem cell transplantation in CLL in the future.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe